RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

NCT06216938 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Vusolimogene oderparepvec (RP1)

Sponsor

Yana Najjar

Collaborators

Replimune, Inc.